135 related articles for article (PubMed ID: 2112055)
1. Experience of the Belgian Society of Medical Oncology with single-administration 5 g/m2 ifosfamide with mesna as second- or third-line therapy in advanced breast cancer.
Paridaens R; Focan C; Michel J; Piccart M; Salamon E; Beauduin M; Closon MT; Tueni E; Vindevoghel A; Majois F
Cancer Chemother Pharmacol; 1990; 26 Suppl():S63-5. PubMed ID: 2112055
[TBL] [Abstract][Full Text] [Related]
2. Toxicity and response to high-dose ifosfamide + mesna as salvage therapy for advanced breast cancer.
Steger GG; Dittrich C; Schlappack O; Mader R; Herold C; Brade WP; Keller A; Moser K
J Cancer Res Clin Oncol; 1988; 114(6):602-4. PubMed ID: 3144554
[TBL] [Abstract][Full Text] [Related]
3. High-dose ifosfamide and mesna in advanced breast cancer. A phase II study.
Sanchiz F; Milla A
Cancer Chemother Pharmacol; 1990; 26 Suppl():S91-2. PubMed ID: 2112057
[TBL] [Abstract][Full Text] [Related]
4. High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma.
Stuart-Harris RC; Harper PG; Parsons CA; Kaye SB; Mooney CA; Gowing NF; Wiltshaw E
Cancer Chemother Pharmacol; 1983; 11(2):69-72. PubMed ID: 6414732
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of paclitaxel and ifosfamide as a salvage treatment in metastatic breast cancer.
Murad AM; Guimaraes RC; Amorim WC; Morici AC; Ferreira-Filho AF; Schwartsmann G
Breast Cancer Res Treat; 1997 Aug; 45(1):47-53. PubMed ID: 9285116
[TBL] [Abstract][Full Text] [Related]
6. Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients.
Coriat R; Mir O; Camps S; Ropert S; Billemont B; Leconte M; Larousserie F; Anract P; Alexandre J; Goldwasser F
Cancer Chemother Pharmacol; 2010 Feb; 65(3):491-5. PubMed ID: 19588140
[TBL] [Abstract][Full Text] [Related]
7. Phase II clinical trial of carboplatin, ifosfamide, with oral mesna for metastatic breast carcinoma.
Turrill M; Spicer DV; Kelley AS; Herman RL; Russell CA; Muggia FM
Cancer Invest; 1995; 13(2):160-4. PubMed ID: 7874569
[TBL] [Abstract][Full Text] [Related]
8. High-dose ifosfamide with mesna uroprotection in Ewing's sarcoma.
Jürgens H; Exner U; Kühl J; Ritter J; Treuner J; Weinel P; Winkler K; Göbel U
Cancer Chemother Pharmacol; 1989; 24 Suppl 1():S40-4. PubMed ID: 2503258
[TBL] [Abstract][Full Text] [Related]
9. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules.
Antman KH; Elias A; Ryan L
Semin Oncol; 1990 Apr; 17(2 Suppl 4):68-73. PubMed ID: 2110386
[TBL] [Abstract][Full Text] [Related]
10. A phase 2 trial of ifosfamide/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy.
Sørensen P; Pfeiffer P; Bertelsen K
Gynecol Oncol; 1995 Jan; 56(1):75-8. PubMed ID: 7821851
[TBL] [Abstract][Full Text] [Related]
11. Ifosfamide and mesna at high doses for the treatment of cancer of the cervix: a GETLAC study.
Cervellino JC; Araujo CE; Pirisi C; Sanchez O; Brosto M; Rossi R
Cancer Chemother Pharmacol; 1990; 26 Suppl():S1-3. PubMed ID: 2112052
[TBL] [Abstract][Full Text] [Related]
12. Continuous infusion of vincristine, ifosfamide and epirubicin over 6 weeks in treatment-resistant advanced breast cancer.
Gurney H; Harnett P; Stuart-Harris R; Kefford R
Eur J Cancer; 1995 Oct; 31A(11):1773-7. PubMed ID: 8541098
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of ifosfamide/mesna with doxorubicin for adult soft tissue sarcoma.
Cantwell BM; Carmichael J; Ghani S; Harris AL
Cancer Chemother Pharmacol; 1988; 21(1):49-52. PubMed ID: 3124971
[TBL] [Abstract][Full Text] [Related]
14. A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study.
Graziano SL; Herndon JE; Richards F; DiFino S; Modeas C; Duggan DB; Green MR
Cancer; 1993 Jul; 72(1):62-8. PubMed ID: 8389667
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study.
Sutton GP; Blessing JA; Homesley HD; Berman ML; Malfetano J
J Clin Oncol; 1989 Nov; 7(11):1672-6. PubMed ID: 2509641
[TBL] [Abstract][Full Text] [Related]
16. Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.
Dechant KL; Brogden RN; Pilkington T; Faulds D
Drugs; 1991 Sep; 42(3):428-67. PubMed ID: 1720382
[TBL] [Abstract][Full Text] [Related]
17. Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies.
Sutton GP; Blessing JA; Photopulos G; Berman ML; Homesley HD
Semin Oncol; 1989 Feb; 16(1 Suppl 3):68-72. PubMed ID: 2539647
[TBL] [Abstract][Full Text] [Related]
18. High-dose ifosfamide with mesna uroprotection: a phase I study.
Elias AD; Eder JP; Shea T; Begg CB; Frei E; Antman KH
J Clin Oncol; 1990 Jan; 8(1):170-8. PubMed ID: 2104923
[TBL] [Abstract][Full Text] [Related]
19. Ifosfamide/etoposide and mesna uroprotection in advanced breast cancer.
Manegold C; Worst P; Bickel J; Schmid H; Drings P; Kaufmann M
Cancer Chemother Pharmacol; 1990; 26 Suppl():S87-90. PubMed ID: 2112056
[TBL] [Abstract][Full Text] [Related]
20. Dosing and side-effects of ifosfamide plus mesna.
Brade WP; Herdrich K; Kachel-Fischer U; Araujo CE
J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S164-86. PubMed ID: 1795007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
